Sign Out
Exemestane is indicated for the adjuvant treatment of postmenopausal women with oestrogen-receptor positive invasive early breast cancer, following 2-3 years of initial adjuvant tamoxifen therapy.
Exemestane is indicated for the treatment of advanced breast cancer in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy. Efficacy has not been demonstrated in patients with oestrogen-receptor negative status.
